SPCC (Sharing Progress in Cancer Care) shared on LinkedIn about a recent paper by Matti Aapro et al. published on Taylor and Francis:
“Denosumab biosimilar offers an opportunity to close treatment gaps in osteoporosis and cancer-treatment related bone loss, improving accessibility and affordability, while maintaining high standards of efficacy and safety.
They represent a key step toward a more sustainable, equitable oncology and supportive care ecosystem, ensuring that more patients can benefit from effective therapies.
Congratulations to the authors for this important contribution.”
Title: Biosimilars in osteoporosis treatment: focus on denosumab
Authors: Matti Aapro ,Peyman Hadji ,Daniele Santini ,Ralf Schmidmaier, Richard Eastell
More insights from SPCC.